[2-(4-Cyanomethylphenylamino)-quinazolin-4-yl]-(5-cyclopropyl-2H-pyrazol-3-yl)-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: [2-(4-Cyanomethylphenylamino)-quinazolin-4-yl]-(5-cyclopropyl-2H-pyrazol-3-yl)-amine
• 英文别名: [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile；2-[4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]amino]phenyl]acetonitrile
• 化学式: C₂₂H₁₉N₇
• 分子量: 381.44
• InChiKey: NVMCVWOODOWOLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  102
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  对氨基苯乙腈 、 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)quinazolin-4-amine 在 盐酸 作用下， 以 水 、 叔丁醇 为溶剂， 以83 %的产率得到[2-(4-Cyanomethylphenylamino)-quinazolin-4-yl]-(5-cyclopropyl-2H-pyrazol-3-yl)-amine
  参考文献：
  名称：

  KR20230005714A

  摘要：

  公开号：

文献信息

• Pyrazole compounds useful as protein kinase inhibitors
  申请人：Bebbington David

  公开号：US20050038023A1

  公开（公告）日：2005-02-17

  This invention describes novel pyrazole compounds of formula IIIa: wherein R 1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x , R y , R 2 ; and R 2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

  这项发明描述了公式IIIa的新型吡唑化合物：其中R1是T-Ring D，其中环D是选择自芳基、杂芳基、杂环基或碳环基的5-7成员单环或8-10成员双环环；Rx、Ry、R2和R2'如规范中描述。这些化合物可用作蛋白激酶抑制剂，特别是作为Aurora-2和GSK-3的抑制剂，用于治疗癌症、糖尿病和阿尔茨海默病等疾病。
• Pyrazole compounds useful as protein kinase inhititors
  申请人：——

  公开号：US20030004161A1

  公开（公告）日：2003-01-02

  This invention describes novel pyrazole compounds of formula I′: 1 wherein Q′ is —O—, —C(R 6′ ) 2 —, 1,2-cyclopropanediyl, 1,2-cyclobutanediyl, or 1,3-cyclopropanediyl, and R 1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x and R y are independently selected from T-R 3 or L-Z-R 3 or R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 heteroatoms; and R 2 and R 2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

  这项发明描述了一种新颖的吡唑类化合物，化学式为I′:1其中Q′为—O—、—C(R6′)2—、1,2-环丙烷二基、1,2-环丁烷二基或1,3-环丙烷二基，R1为T-Ring D，其中Ring D为从芳香族、杂芳基、杂环基或碳环基中选择的5-7成员单环或8-10成员双环；Rx和Ry分别独立选择自T-R3或L-Z-R3或Rx和Ry与它们之间的原子结合形成融合、不饱和或部分不饱和、含有0-3个杂原子的5-7成员环；R2和R2′如规范中描述。这些化合物可用作蛋白激酶抑制剂，特别是作为Aurora-2和GSK-3的抑制剂，用于治疗癌症、糖尿病和阿尔茨海默病等疾病。
• [EN] 2,4-DIAMINOPYRIMIDINE BICYCLES FOR TREATING CANCER<br/>[FR] BICYCLES DE 2,4-DIAMINOPYRIMIDINE POUR LE TRAITEMENT DU CANCER
  申请人：KAPOOR TARUN M

  公开号：WO2020118183A1

  公开（公告）日：2020-06-11

  A genus of quinazoline and pyrrolo[3,2-d]pyrimidine derivatives is disclosed. The compounds are of the genus (I). The compounds selectively inhibit subfamilies of AAA+ proteins and TrkA-C. They are useful in the treatment of Alzheimer's disease and as anticancer agents.

  本发明揭示了一类喹唑啉和吡咯并[3,2-d]嘧啶衍生物的属。这些化合物属于属(I)。这些化合物具有选择性地抑制AAA+蛋白质和TrkA-C亚家族。它们在治疗阿尔茨海默病和作为抗癌剂方面有用。
• PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：Bebbington David

  公开号：US20090312543A1

  公开（公告）日：2009-12-17

  This invention describes novel pyrazole compounds of formula IIIa: wherein R 1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x , R y , R 2 , and R 2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

  本发明描述了式IIIa的新型吡唑化合物： 其中R1是T-Ring D，其中环D是5-7成员单环或8-10成员双环，选自芳基，杂芳基，杂环基或碳环基；Rx，Ry，R2和R2'如说明书所述。该化合物可用作蛋白激酶抑制剂，特别是用于抑制Aurora-2和GSK-3，治疗癌症，糖尿病和阿尔茨海默病等疾病。
• Methods and Compositions for Modulating IRE1, SRC, and ABL Activity
  申请人：Walter Peter

  公开号：US20110319436A1

  公开（公告）日：2011-12-29

  Disclosed herein are, inter alia, compositions for modulating Ire1, Src, or Abl, methods for identifying modulating activity in test compounds, and methods for treating diseases caused by the activity or inactivity of Ire1, Src, or Abl.

  本文披露了用于调节Ire1、Src或Abl的组合物，识别测试化合物中调节活性的方法，以及治疗由Ire1、Src或Abl的活性或不活性引起的疾病的方法。